BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

664 related articles for article (PubMed ID: 14630271)

  • 21. Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial.
    Chun SG; Hu C; Choy H; Komaki RU; Timmerman RD; Schild SE; Bogart JA; Dobelbower MC; Bosch W; Galvin JM; Kavadi VS; Narayan S; Iyengar P; Robinson CG; Wynn RB; Raben A; Augspurger ME; MacRae RM; Paulus R; Bradley JD
    J Clin Oncol; 2017 Jan; 35(1):56-62. PubMed ID: 28034064
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Dose Escalation Clinical Trial of Single-Fraction Carbon Ion Radiotherapy for Peripheral Stage I Non-Small Cell Lung Cancer.
    Yamamoto N; Miyamoto T; Nakajima M; Karube M; Hayashi K; Tsuji H; Tsujii H; Kamada T; Fujisawa T
    J Thorac Oncol; 2017 Apr; 12(4):673-680. PubMed ID: 28007628
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial.
    Rosenman JG; Halle JS; Socinski MA; Deschesne K; Moore DT; Johnson H; Fraser R; Morris DE
    Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):348-56. PubMed ID: 12243807
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
    Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
    Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose escalated, hypofractionated radiotherapy using helical tomotherapy for inoperable non-small cell lung cancer: preliminary results of a risk-stratified phase I dose escalation study.
    Adkison JB; Khuntia D; Bentzen SM; Cannon GM; Tome WA; Jaradat H; Walker W; Traynor AM; Weigel T; Mehta MP
    Technol Cancer Res Treat; 2008 Dec; 7(6):441-7. PubMed ID: 19044323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial.
    Hayman JA; Martel MK; Ten Haken RK; Normolle DP; Todd RF; Littles JF; Sullivan MA; Possert PW; Turrisi AT; Lichter AS
    J Clin Oncol; 2001 Jan; 19(1):127-36. PubMed ID: 11134205
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Phase I clinical trial of dose escalation on three dimensional conformal radiation therapy for non-small cell lung cancer].
    Wu K; Jiang G; Liao Y; Wang L; Qian H; Yang H; Zhang Z; Hu C; Zhao S
    Zhongguo Fei Ai Za Zhi; 2000 Oct; 3(5):322-5. PubMed ID: 20979712
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial.
    Socinski MA; Morris DE; Halle JS; Moore DT; Hensing TA; Limentani SA; Fraser R; Tynan M; Mears A; Rivera MP; Detterbeck FC; Rosenman JG
    J Clin Oncol; 2004 Nov; 22(21):4341-50. PubMed ID: 15514375
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.
    Choi NC; Herndon JE; Rosenman J; Carey RW; Chung CT; Bernard S; Leone L; Seagren S; Green M
    J Clin Oncol; 1998 Nov; 16(11):3528-36. PubMed ID: 9817271
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with three-dimensional conformal radiotherapy.
    Singh AK; Lockett MA; Bradley JD
    Int J Radiat Oncol Biol Phys; 2003 Feb; 55(2):337-41. PubMed ID: 12527046
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
    Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase I/II study to evaluate accelerated fractionation via concomitant boost for squamous, adeno, and large cell carcinoma of the lung: report of Radiation Therapy Oncology Group 84-07.
    Byhardt RW; Pajak TF; Emami B; Herskovic A; Doggett RS; Olsen LA
    Int J Radiat Oncol Biol Phys; 1993 Jun; 26(3):459-68. PubMed ID: 8390420
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Non-small cell lung cancer in stages I-IIIB: Long-term results of definitive radiotherapy with doses ≥ 80 Gy in standard fractionation.
    Wurstbauer K; Weise H; Deutschmann H; Kopp P; Merz F; Studnicka M; Nairz O; Sedlmayer F
    Strahlenther Onkol; 2010 Oct; 186(10):551-7. PubMed ID: 20936459
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma.
    Bradley JD; Ieumwananonthachai N; Purdy JA; Wasserman TH; Lockett MA; Graham MV; Perez CA
    Int J Radiat Oncol Biol Phys; 2002 Jan; 52(1):49-57. PubMed ID: 11777621
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: clinical and dosimetric factors analysis.
    Claude L; Pérol D; Ginestet C; Falchero L; Arpin D; Vincent M; Martel I; Hominal S; Cordier JF; Carrie C
    Radiother Oncol; 2004 May; 71(2):175-81. PubMed ID: 15110451
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intensity-modulated radiotherapy for locally advanced non-small-cell lung cancer: a dose-escalation planning study.
    Lievens Y; Nulens A; Gaber MA; Defraene G; De Wever W; Stroobants S; Van den Heuvel F;
    Int J Radiat Oncol Biol Phys; 2011 May; 80(1):306-13. PubMed ID: 20888706
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Phase II study of synchronous three-dimensional conformal boost to the gross tumor volume for patients with unresectable Stage III non-small-cell lung cancer: results of Korean Radiation Oncology Group 0301 study.
    Cho KH; Ahn SJ; Pyo HR; Kim KS; Kim YC; Moon SH; Han JY; Kim HT; Koom WS; Lee JS
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1397-404. PubMed ID: 19117690
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation.
    Grills IS; Yan D; Martinez AA; Vicini FA; Wong JW; Kestin LL
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):875-90. PubMed ID: 14529795
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Late course three-dimensional conformal radiotherapy in patients with stage III non-small cell lung cancer].
    Wang XC; Wang SY; Yang S; Ding Y; Shang Y
    Di Yi Jun Yi Da Xue Xue Bao; 2005 Jun; 25(6):726-8. PubMed ID: 15958322
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis.
    Kong FM; Hayman JA; Griffith KA; Kalemkerian GP; Arenberg D; Lyons S; Turrisi A; Lichter A; Fraass B; Eisbruch A; Lawrence TS; Ten Haken RK
    Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1075-86. PubMed ID: 16647222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.